Adult Dosing

Hyperphosphatemia in ESRD

• 1334-2668 mg PO qd divided bid with meal. Adjust dose to keep serum phosphate < 6 mg/dL as long as hypercalcemia does not develop

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Hyperphosphatemia in ESRD

• Hypersensitivity to any of the ingredients of the product
• Hypercalcemia
• Serum calcium-phosphate product > 66

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• Always start with low dose and should not be increased without careful monitoring of serum calcium
• Avoid use of concurrent calcium supplements as it may develop hypercalcemia in patients with ESRD
• Monitor for progressive hypercalcemia due to overdose of calcium acetate which may be severe and may require emergency measures
• Hypercalcemia due to overdosage may precipitate cardiac arrhythmias. Avoid use in patients on digitalis
• Monitor serum calcium level twice weekly during the early dose adjustment period as chronic hypercalcemia may occur leading to vascular calcification and other soft-tissue calcification
• Reduce dosage or discontinue therapy immediately depending on the severity of hypercalcemia
• Do not allow serum calcium-phosphate product (CaXP) product to exceed 66
• Radiographic evaluation of suspect anatomical region should be performed in early detection of soft tissue calcification

Cautions: Use cautiously in

• Renal impairment
• GI obstruction
• Arrhythmias
• Hypercalciuria
• Hypophosphatemia
• Dehydration
• Hyperparathyroidism
• Vitamin D toxicity

Supplemental Patient Information

• Advise patient to avoid use of non prescription antacids

Pregnancy Category:C

Breastfeeding: Probably Safe

• HEMA: Hypercalcemia, hypomagnesemia
• CNS: Confusion, delirium, stupor, coma
• GU: Nephrolithiasis, hypercalciuria
• GI: Nausea, constipation, anorexia, vomiting
• MISC: Allergic reactions, pruritus

• Phosphate binders; essential component and participant in physiologic systems and reactions; binds intestinal phosphate
• Systemically absorbed; approximately 40% (fasting conditions) and approximately 30% (nonfasting conditions)
• Metabolism: Not known; CYP450; Unknown
• Primarily excreted in feces, urine
• Half-life: Unknown

US Trade Name(s)

• Calphron
• Eliphos
• PhosLo Gelcaps
• Phoslyra

US Availability

calcium acetate (generic)

• CAPS: 667 mg (eq. to 169 mg calcium)
• TABS: 667 mg (eq. to 169 mg calcium)

Calphron

• OTC CAPS: 667 mg (eq. to 169 mg calcium)

Eliphos

• TABS: 667 mg (eq. to 169 mg calcium)

PhosLo Gelcaps

• CAPS: 667 mg (eq. to 169 mg calcium)

Phoslyra

• SOLN: 667 mg/5 mL (eq. to 169 mg calcium)

Canadian Trade Name(s)

• PhosLo

Canadian Availability

PhosLo

• TABS: 667 mg

UK Trade Name(s)

• Phosex
• PhosLo

UK Availability

Phosex

• TABS: 1000 mg

PhosLo

• CAPS: 667 mg

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Nutrition/Electrolytes

Minerals & Electrolytes

Pricing data from www.DrugStore.com in U.S.A.

• PhosLo 667 MG CAPS [Bottle] (FRESENIUS)
  200 mg = $197.99
  600 mg = $567.54
• Calcium Acetate 667 MG CAPS [Bottle] (ROXANE)
  30 mg = $28.99
  60 mg = $46.97
• Eliphos 667 MG TABS [Bottle] (HAWTHORN PHARMACEUTICALS)
  30 mg = $26.39
  90 mg = $54.96

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

• Calcium acetate 667 MG Oral Capsule (NCS Healthcare of KY, Inc. dba Vangard Labs)
• Calcium acetate 667 MG Oral Capsule (Roxane Laboratories, Inc)
• Calcium acetate 667 MG Oral Capsule (Sandoz Inc)
• Calcium acetate 667 MG Oral Capsule (State of Florida DOH Central Pharmacy)
• Phoslo 667 MG Oral Capsule (Fresenius Medical Care North America)
• Phoslo 667 MG Oral Capsule (Physicians Total Care, Inc.)
• Phoslo 667 MG Oral Tablet (Nabi Biopharmaceuticals)